The guidelines for clinical trials of anti-tumor drugs issued by the State Food and Drug Administration clearly indicate that, with the consent of the subjects, it is recommended to obtain their body fluids, blood/serum, tissues for the detection of relevant tumor markers and to reasonably predict them. Possible curative effect. Cytokines are synthesized and secreted by immune cells (such as mononuclear, macrophage, T cells, B cells, NK cells, etc.) and certain non-immune cells (endothelial cells, epidermal cells, fibroblasts, etc.). A class of small molecule proteins with a wide range of biological activities. After the use of anti-tumor drugs, changes in cytokines such as IL-2, TNF-alpha, etc. are very important indicators of the efficacy of tumor drugs. In addition, tumor-targeted drugs targeting cytokines under development, such as the new anticancer drug NKTR-214, which targets the IL-2 signaling pathway and specifically activates the IL-2 receptor complex, have been shown to be evident It inhibits the growth of malignant tumors and is effective against a variety of malignant tumors. Therefore, cytokines are important detection target proteins in clinical trials of tumor-targeted therapeutic drugs. In addition to cytokines, some markers related to tumor treatment effects, such as HE4/WFDC2, Chitinase 3-like 1/YKL-40, MICA and CA-125, are detected in body fluids, and the evaluation of antitumor drugs is extremely extreme. Significance. Previous methods for detecting cytokines and tumor markers in clinical trials of anti-tumor drugs, such as ELISA and Multiplex, have many manual operations, are difficult to standardize, and have large deviations between experiments, resulting in insufficient evaluation of clinical treatment effects. accurate. In addition, the non-specific binding and false positive phenomena accompanying these techniques have a very large impact on the evaluation of therapeutic effects. And repeating a large number of tests can also waste valuable time to market. Recently, Roche Pharmaceuticals, the world's largest anti-cancer drug research and development giant, and its scientists at the Basel Research Center have developed a rapid detection platform for cytokines and tumor markers in clinical trials of anticancer drugs using Ella simple plex technology. Dr. Martina Their, the director of the Center's Immunology Laboratory, evaluated the technology to have the following advantages: 1) very good specificity; 2) 25 ul samples for 4 target proteins, saving precious samples; 3) automated testing and saving manpower And to ensure the standardization of experiments; 4) 1 hour to obtain results, is the fastest detection technology, greatly shortening the time for drugs to pass clinical trials and market. Ella simple plex multi-factor multi-sample immunoassay system, the global leading brand of protein automated detection and development, has been listed by the US proteinsimple company in January 2015. Hotel Digital Fingerprint Safe Hotel Safe Box,Digital Hotel Safes Box,Hotel Digital Fingerprint Safe,Money Deposit Electronic Safe Ningbo Reliance Security Technology CO.,Ltd , https://www.reliancesafes.com